Advances of bifunctional anti-PD-L1/TGF-β fusion protein M7824

doi:10.3760/cma.j.issn.1673-422X.2019.05.006

Abstract

Abstract: With the development of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors, the second generation of combined immunosuppressive agents emerge as the times require. As a bifunctional anti-PD-L1/transforming growth factor-β (TGF-β) fusion protein, M7824 can antagonize PD-L1 pathway and trap TGF-β at the same time, which can effectively enhance the immune response and reduce the occurrence of immune escape and drug resistance. The drug has achieved remarkable results in many preclinical studies, however, the indications, safety and efficacy still need to be confirmed by large-scale clinical research data.

Key words: Recombinant fusion proteins, Transforming growth factor β, PD-L1, M7824

Hu Mengxue, Xu Bin, Yu Jinming, Song Qibin. Advances of bifunctional anti-PD-L1/TGF-β fusion protein M7824[J]. Journal of International Oncology, 2019, 46(5): 281-284.

References

［1］ Guo L, Zhang Y, Zhang L, et al. MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer［J］. Tumour Biol, 2016, 37(1): 115-125. DOI: 10.1007/s13277-015-4374-2. ［2］ Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease［J］. Nat Rev Drug Discov, 2012, 11(10): 790-811. DOI: 10.1038/nrd3810. ［3］ Ravi R, Noonan KA, Pham V, et al. Bifunctional immune checkpointtargeted antibodyligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy［J］. Nat Commun, 2018, 9(1): 741. DOI: 10.1038/s41467-017-02696-6. ［4］ Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumourassociated macrophages inhibits phagocytosis and tumour immunity［J］. Nature, 2017, 545(7655): 495-499. DOI: 10.1038/nature22396. ［5］ Moustakas A, Heldin CH. Mechanisms of TGFβ-induced epithelialmesenchymal transition［J］. J Clin Med, 2016, 5(7). pii: E63. DOI: 10.3390/jcm5070063. ［6］ Bai WD, Ye XM, Zhang MY, et al. MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer［J］. Int J Cancer, 2014, 135(6): 1356-1368. DOI: 10.1002/ijc.28782. ［7］ Lin RL, Zhao LJ. Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer［J］. Cancer Biol Med, 2015, 12(4): 385-393. DOI: 10.7497/j.issn.20953941.2015.0015. ［8］ Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells［J］. Nature, 2018, 554(7693): 544-548. DOI: 10.1038/nature25501. ［9］ Duan J, Liu X, Chen H, et al. Impact of PDL1, transforming growth factorβ expression and tumor-infiltrating CD8⁺T cells on clinical outcome of patients with advanced thymic epithelial tumors［J］. Thorac Cancer, 2018, 9(11): 1341-1353. DOI: 10.1111/1759-7714.12826. ［10］ Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity［J］. Immunol Rev, 2010, 236: 219-242. DOI: 10.1111/j.1600-065x.2010.00923.x. ［11］ Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells［J］. J Exp Med, 2009, 206(13): 3015-3029. DOI: 10.1084/jem.20090847. ［12］ Morikawa M, Derynck R, Miyazono K. TGFβ and the TGFβ family: contextdependent roles in cell and tissue physiology［J］. Cold Spring Harb Perspect Biol, 2016, 8(5). pii: a021873. DOI: 10.1101/cshperspect.a021873. ［13］ Lan Y, Zhang D, Xu C, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β［J］. Sci Transl Med, 2018, 10(424). pii: eaan5488. DOI: 10.1126/scitranslmed.aan5488. ［14］ Knudson KM, Hicks KC, Luo X, et al. M7824, a novel bifunctional antiPD-L1/TGFβ Trap fusion protein, promotes antitumor efficacy as monotherapy and in combination with vaccine［J］. OncoImmunology, 2018, 7(5): e1426519. DOI: 10.1080/2162402X.2018.1426519. ［15］ Jochems C, Tritsch SR, Pellom ST, et al. Analyses of functions of an antiPD-L1/TGFβR2 bispecific fusion protein (M7824)［J］. Oncotarget, 2017, 8(43): 75217-75231. DOI: 10.18632/oncotarget.20680. ［16］ Strauss J, Heery CR, Schlom J, et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors［J］. Clin Cancer Res, 2018, 24(6): 1287-1295. DOI: 10.1158/1078-0432.CCR-17-2653. ［17］ Dovedi SJ, Adlard AL, LipowskaBhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade［J］. Cancer Res, 2014, 74(19): 5458-5468. DOI: 10.1158/0008-5472.CAN-14-1258. ［18］ Grenga I, Donahue RN, Gargulak ML, et al. AntiPDL1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immunemediated recognition and lysis［J］. Urol Oncol, 2018, 36(3): 93. e1-e93. e11. DOI: 10.1016/j.urolonc.2017.09.027. ［19］ David JM, Dominguez C, McCampbell KK, et al. A novel bifunctional antiPD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells［J］. Oncoimmunology, 2017, 6(10): e1349589. DOI: 10.1080/2162402X.2017.1349589. ［20］ Liu L, Liu X, Ren X, et al. Smad2 and Smad3 have differential sensitivity in relaying TGFβ signaling and inversely regulate early lineage specification［J］. Sci Rep, 2016, 6: 21602. DOI: 10.1038/srep21602. ［21］ Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as firstline treatment in cisplatinineligible patients with locally advanced and metastatic urothelial carcinoma: a singlearm, multicentre, phase 2 trial［J］. Lancet, 2017, 389(10064): 67-76. DOI: 10.1016/S0140-6736(16)32455-2. ［22］ Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinumtreated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, openlabel, phase 3 randomised controlled trial［J］. Lancet, 2018, 391(10122): 748-757. DOI: 10.1016/S0140-6736(17)33297-X. ［23］ Terabe M, Robertson FC, Clark K, et al. Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy［J］. Oncoimmunology, 2017, 6(5): e1308616. DOI: 10.1080/2162402X.2017.1308616. ［24］ Park BV, Freeman ZT, Ghasemzadeh A, et al. TGF-β1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer［J］. Cancer Discov, 2016, 6(12): 1366-1381. DOI: 10.1158/2159-8290.CD-15-1347. ［25］ Luis G, Tae K, David VB, et al. Results from a secondline (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctiona fusion protein targeting TGF-β and PD-L1［J］. J Clin Oncol, 2018, 36 (15_Suppl): 9017. DOI: 10.1200/JCO.2018.36.15_suppl.9017. ［26］ Julius S, Margaret GM, Jason R, et al. Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers［J］. J Clin Oncol, 2018, 36 (15_Suppl): 3007. DOI: 10.1200/JCO.2018.36.15_suppl.3007. ［27］ Yoo C, oh DY, Choi HJ, et al. AB053. P-21. M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): efficacy by BTC subtype［J］. ESMO, 2019, In press. DOI: 10.21037/hbsn.2019.AB053.

[1]	Wang Yue, Hu Qun, Hou Yingwei. Research progress in influences of epigenetic modifications on PD-L1 expression in tumors [J]. Journal of International Oncology, 2022, 49(6): 345-348.
[2]	Ning Tingting, Hu Qinyong. Research progress of metformin in tumor immunotherapy [J]. Journal of International Oncology, 2022, 49(5): 292-295.
[3]	Ding Xinjing, Ding Jianghua. Research progress on the correlation between dermatological immune-related adverse events and clinical outcome of PD-1/PD-L1 inhibitors [J]. Journal of International Oncology, 2022, 49(4): 225-228.
[4]	Xie Hongxia, Zuo Jinhui, Liao Dongying, Deng Renfen, Yao Yang, Jia Yingjie, Li Xiaojiang, Kong Fanming. Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(2): 111-115.
[5]	Ou Huiyi, Wang Yue, Peng Chenghong. Correlation between PD-L1 and Tregs in tumor immunity and immunotherapy [J]. Journal of International Oncology, 2021, 48(6): 350-353.
[6]	Ding Yan, Wang Hongyan. Advances of PD-1/PD-L1 inhibitors in the treatment of esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2021, 48(2): 113-116.
[7]	Zhao Lili, Zhao Wenwen, Feng Qingqing, Zhao Wenfei, Zhang Xue, Jing Wenjun, Wei Hongmei. Effects of silencing PD-L1 expression on biological behaviors of gastric cancer cells [J]. Journal of International Oncology, 2021, 48(12): 705-710.
[8]	Cao Chun, He Wenqi, Yan Jun. Application of immune checkpoint inhibitors in the treatment of small cell lung cancer [J]. Journal of International Oncology, 2021, 48(12): 747-750.
[9]	Xue Chen, Zhao Yue, Shi Guang, Tang Yan. Research progress of PD-1/PD-L1 inhibitors in ovarian cancer [J]. Journal of International Oncology, 2020, 47(5): 312-315.
[10]	Xu Yangtao, Chen Biao, He Xiaoqin, Xu Ximing. Research progress of hyperprogressive disease after immunotherapy [J]. Journal of International Oncology, 2020, 47(12): 737-740.
[11]	Song Bo, Wu Mingxin, Jia Yingjie, Li Xiaojiang. Research progress of immune-related pneumonia caused by PD-1/PD-L1 inhibitor [J]. Journal of International Oncology, 2020, 47(10): 627-629.
[12]	Zhang Lizhuo, Qian Yangyang, Zheng Guowan, Ge Minghua. Mechanism study of PD-1/PD-L1 in tumor and its value of diagnosis and treatment of thyroid cancer [J]. Journal of International Oncology, 2020, 47(1): 39-42.
[13]	Bai Xinya, Zhang jinmeng, Sun Yang, An Yongheng . Application of immune checkpoint inhibitors in the comprehensive treatment of advanced non-small cell lung cancer [J]. Journal of International Oncology, 2019, 46(8): 500-504.
[14]	Hu Gengwei1, Zhang Ying2, Wu Zhihao3. Mechanism study and immunotherapy of immune checkpoint PD-1/PD-L1 [J]. Journal of International Oncology, 2019, 46(2): 87-90.
[15]	Qi Ruili, Wang Huaqing. Research progress of tumor vascular targeting drugs combined with PD-1/PD-L1 antibody in the treatment of digestive system tumors [J]. Journal of International Oncology, 2019, 46(12): 750-754.